Researchers theorized on whether mass spectrometry-based analysis of the presented HLA ligands of cancer cell lines can be used to identify a tumor-associated HLA ligand.
Researchers sought to determine whether glofitamab monotherapy would have high preliminary response rates in patients with R/R non-Hodgkin lymphoma.
Researchers sought to determine whether loncastuximab tesirine would have durable responses in heavily pretreated patients with R/R DLBCL.
A single dose of cilta-cel yielded early, deep, and durable responses in heavily pre-treated patients with relapsed/refractory multiple myeloma.
Researchers sought to determine the optimal benefit/risk profile for ponatinib in patients with resistant/intolerant chronic-phase chronic myeloid leukemia.
Researchers sought to determine whether gilteritinib would have efficacy in patients with relapsed/refractory AML who had received prior TKI therapy.
Researchers sought to determine whether pevonedistat plus azacitidine would have efficacy in patients with higher-risk MDS compared with azacitidine alone.
Researchers sought to determine whether tafasitamab with lenalidomide would improve outcomes for patients with relapsed/refractory DLBCL.
Researchers sought to determine whether GVHD prophylaxis with posttransplant cyclophosphamide following allo-HSCT would be associated with a higher risk of infection.
Researchers sought to identify patients with germline predisposition syndromes without syndromic features using an algorithmic approach compared with classic methods.
